To the Editor We read with interest the article by Lees and colleagues1 studying opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations. We have some concerns about their study.
First, the fact that several participating centers and relatively few patients were involved in the current study might be a source of variations. Seventy-one participating centers enrolled 485 patients during the period from 2011 through 2013. Thus, on average, each participating center enrolled 1 patient every 4 months. This extremely low rate may suggest that inclusion in the trial was selective and not representative of patients with Parkinson disease in general.
Zhang Y, Huang X. Concerns Regarding Opicapone as Adjunct to Levodopa Therapy. JAMA Neurol. 2017;74(7):872–873. doi:10.1001/jamaneurol.2017.0723
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.